CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis - PubMed (original) (raw)
CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis
Fiona C McKay et al. J Autoimmun. 2008 Aug.
Abstract
Aberrant regulatory T cell populations, characterised by a wide array of CD markers, have been identified in many autoimmune diseases. CD127 has recently been identified as a specific marker for the CD4(+)CD25(Hi) (Tregs) subset. CD127 is the first non-HLA gene to have its association with multiple sclerosis widely replicated. We demonstrate that the regulatory or suppressor T cells CD4(+)CD25(Hi) (Tregs), CD8(+)CD28(-), and CD3(+)CD56(+) (NKT) all produce low levels of CD127, and so could be at a disadvantage in survival and/or proliferation where IL7 is limiting. The remissions seen in relapsing remitting multiple sclerosis (RRMS) could be driven by regulatory T cells, and the absence of remissions seen in primary progressive MS (PPMS) may point to a particularly reduced function of this cell subset. We found that the proportions of CD4(+)FoxP3(+)CD25(Hi) regulatory T cells were not aberrant in PPMS. There was, however, a trend towards reduced FoxP3 expression per cell in this fraction (p<0.083), which has been highly correlated with suppressor function. Notably, we found that the target of regulatory T cells, the CD4(+)CD25(-) cells, was in excess (p<0.009); and in PPMS a protective CD127 haplotype is correlated with higher CD127 expression (p<0.01). These data support further investigations into the regulatory T cell immunophenotype in MS.
Similar articles
- CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D. Shen LS, et al. Clin Immunol. 2009 Apr;131(1):109-18. doi: 10.1016/j.clim.2008.11.010. Epub 2009 Jan 18. Clin Immunol. 2009. PMID: 19153062 - Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, D'hooghe MB, Dubois B, Raus J, Stinissen P. Venken K, et al. J Neurosci Res. 2006 Jun;83(8):1432-46. doi: 10.1002/jnr.20852. J Neurosci Res. 2006. PMID: 16583400 - T regulatory cells lacking CD25 are increased in MS during relapse.
Fransson M, Burman J, Lindqvist C, Atterby C, Fagius J, Loskog A. Fransson M, et al. Autoimmunity. 2010 Dec;43(8):590-7. doi: 10.3109/08916930903541190. Epub 2010 Apr 7. Autoimmunity. 2010. PMID: 20370571 - CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.
Kuhn A, Beissert S, Krammer PH. Kuhn A, et al. Arch Dermatol Res. 2009 Jan;301(1):71-81. doi: 10.1007/s00403-008-0891-9. Epub 2008 Nov 5. Arch Dermatol Res. 2009. PMID: 18985367 Review. - Disturbed regulatory T cell homeostasis in multiple sclerosis.
Venken K, Hellings N, Liblau R, Stinissen P. Venken K, et al. Trends Mol Med. 2010 Feb;16(2):58-68. doi: 10.1016/j.molmed.2009.12.003. Trends Mol Med. 2010. PMID: 20159585 Review.
Cited by
- Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial.
Shohdy KS, Pillai M, Abbas KS, Allison J, Waddell T, Darlington E, Mohammad S, Hood S, Atkinson S, Simpson K, Morgan D, Nathan P, Kilgour E, Dive C, Thistlethwaite F. Shohdy KS, et al. Immunooncol Technol. 2024 Mar 18;22:100712. doi: 10.1016/j.iotech.2024.100712. eCollection 2024 Jun. Immunooncol Technol. 2024. PMID: 38694705 Free PMC article. - The Impact of Cytomegalovirus Infection on Natural Killer and CD8+ T Cell Phenotype in Multiple Sclerosis.
Perri V, Zingaropoli MA, Pasculli P, Ciccone F, Tartaglia M, Baione V, Malimpensa L, Ferrazzano G, Mastroianni CM, Conte A, Ciardi MR. Perri V, et al. Biology (Basel). 2024 Feb 28;13(3):154. doi: 10.3390/biology13030154. Biology (Basel). 2024. PMID: 38534424 Free PMC article. - The Association of IL7R rs6897932 with Risk of Multiple Sclerosis in Southern Chinese.
Zhao Z, Xue J, Zhuo Z, Zhong W, Liu H. Zhao Z, et al. Neuropsychiatr Dis Treat. 2022 Aug 26;18:1855-1859. doi: 10.2147/NDT.S376066. eCollection 2022. Neuropsychiatr Dis Treat. 2022. PMID: 36052273 Free PMC article. - Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis.
Perdaens O, van Pesch V. Perdaens O, et al. Front Neurol. 2022 Feb 25;12:811518. doi: 10.3389/fneur.2021.811518. eCollection 2021. Front Neurol. 2022. PMID: 35281989 Free PMC article. Review. - NKT and NKT-like Cells in Autoimmune Neuroinflammatory Diseases-Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome.
Zarobkiewicz MK, Morawska I, Michalski A, Roliński J, Bojarska-Junak A. Zarobkiewicz MK, et al. Int J Mol Sci. 2021 Sep 1;22(17):9520. doi: 10.3390/ijms22179520. Int J Mol Sci. 2021. PMID: 34502425 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials